Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | CASP6 | P55212 | 1/20 | 0.46 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.44 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.44 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.40 |
| ▸ | DRD1 | P21728 | 1/20 | 0.38 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.37 |
| ▸ | STS | P08842 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | KIF11 | P52732 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9107953 | 0.83 | ALDH1A1 (0.37) | ALDH1A1KDM4ESMN1; SMN2LMNAL3MBTL1 | |
| SCHEMBL9107191 | 0.82 | KDM4E (0.50) | ALDH1A1KDM4ESMN1; SMN2LMNAL3MBTL1 | |
| SCHEMBL876362 | 0.79 | ALDH1A1 (0.41) | ALDH1A1KDM4ESMN1; SMN2L3MBTL1POLB | |
| SCHEMBL1713491 | 0.77 | KDM4E (0.54) | ALDH1A1KDM4ESMN1; SMN2LMNAL3MBTL1 | |
| SCHEMBL184377 | 0.77 | PARP10 (0.50) | ALDH1A1KDM4ESMN1; SMN2LMNAL3MBTL1 | |
| SCHEMBL9103318 | 0.76 | ALDH1A1 (0.37) | ALDH1A1L3MBTL1POLBCASP6KIF11 | |
| SCHEMBL365790 | 0.76 | POLB (0.46) | ALDH1A1KDM4ESMN1; SMN2LMNAL3MBTL1 | |
| SCHEMBL347307 | 0.76 | ALDH1A1 (0.38) | ALDH1A1KDM4EL3MBTL1POLBKIF11 | |
| SCHEMBL1663469 | 0.75 | PARP10 (0.65) | ALDH1A1KDM4ESMN1; SMN2LMNAL3MBTL1 | |
| SCHEMBL5050902 | 0.75 | PARP10 (0.65) | ALDH1A1KDM4ESMN1; SMN2LMNAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2649053-B1 | PYRIMIDINONE COMPOUNDS FOR USE IN THE TREATMENT OF DISEASES OR CONDITIONS MEDIATED BY LP-PLA2 | GLAXO GROUP LTD (GB) | 2015-11-04 | — | — | EP | disclosed |
| EP-2649053-B1 | PYRIMIDINONE COMPOUNDS FOR USE IN THE TREATMENT OF DISEASES OR CONDITIONS MEDIATED BY LP-PLA2 | GLAXO GROUP LTD (GB) | 2015-11-04 | — | — | EP | disclosed |
| US-9174968-B2 | Pyrimidinone compounds for use in the treatment of diseases or conditions mediated by LP-PLA2 | GLAXO GROUP LIMITED (GB) | 2015-11-03 | — | — | US | disclosed |
| US-9174968-B2 | Pyrimidinone compounds for use in the treatment of diseases or conditions mediated by LP-PLA2 | GLAXO GROUP LIMITED (GB) | 2015-11-03 | — | — | US | disclosed |
| US-20150099756-A1 | PYRIMIDINONE COMPOUNDS FOR USE IN THE TREATMENT OF DISEASES OR CONDITIONS MEDIATED BY LP-PLA2 | GLAXO GROUP LIMITED (GB) | 2015-04-09 | — | — | US | disclosed |
| US-20150099756-A1 | PYRIMIDINONE COMPOUNDS FOR USE IN THE TREATMENT OF DISEASES OR CONDITIONS MEDIATED BY LP-PLA2 | GLAXO GROUP LIMITED (GB) | 2015-04-09 | — | — | US | disclosed |
| US-20140378487-A1 | TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES | GLAXO GROUP LTD (GB) | 2014-12-25 | — | — | US | disclosed |
| US-8871928-B2 | Tricyclic compounds, preparation methods, and their uses | GLAXO GROUP LIMITED (GB) | 2014-10-28 | — | — | US | disclosed |
| US-20140113922-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2014-04-24 | — | — | US | disclosed |
| US-8637536-B2 | Pyrimidinone compounds for use in the treatment of diseases or conditions mediated by Lp-PLA2 | GLAXO GROUP LIMITED (GB) | 2014-01-28 | — | — | US | disclosed |
| US-20120232101-A1 | Novel Compounds | CHAPMAN DAVID (SE) | 2012-09-13 | — | — | US | disclosed |
| WO-2012076435-A1 | PYRIMIDINONE COMPOUNDS FOR USE IN THE TREATMENT OF DISEASES OR CONDITIONS MEDIATED BY LP - PLA2 | GLAXO GROUP LIMITED (GB) | 2012-06-14 | — | — | WO | disclosed |
| WO-2012076435-A1 | PYRIMIDINONE COMPOUNDS FOR USE IN THE TREATMENT OF DISEASES OR CONDITIONS MEDIATED BY LP - PLA2 | GLAXO GROUP LIMITED (GB) | 2012-06-14 | — | — | WO | disclosed |
| US-20120142717-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2012-06-07 | — | — | US | disclosed |
| US-8183251-B2 | 1-[(4S)-4-cyclopropyl-2,5-dioxoimidazolidin-4-yl]-N-methyl-N-{[4-(pyrimidin-5-yloxy)phenyl]methyl}methanesulfonamide; matrix metalloproteinase inhibitors; obstructive airways disease is asthma or chronic obstructive pulmonary disease | ASTRAZENECA AB (SE) | 2012-05-22 | — | — | US | disclosed |
| WO-2012037782-A1 | TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES | GLAXO GROUP LIMITED (GB) | 2012-03-29 | — | — | WO | disclosed |
| EP-2097406-B1 | HYDANTOIN DERIVATIVES USED AS MMP INHIBITORS | ASTRAZENECA AB (SE) | 2011-07-20 | — | — | EP | disclosed |
| EP-2097406-A1 | HYDANTOIN DERIVATIVES USED AS MMP INHIBITORS | Astra Zeneca AB (SE) | 2009-09-09 | — | — | EP | disclosed |
| US-20080221139-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2008-09-11 | — | — | US | disclosed |
| WO-2008065393-A1 | HYDANTOIN DERIVATIVES USED AS MMP INHIBITORS | ASTRAZENECA AB (SE) | 2008-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140113922-A1 | COMPOUNDS | LIPG, PLA2G1B, ENPP2 | ALDH1A1 3079/4885KDM4E 3871/4885SMN1; SMN2 3782/4885 |
| US-20120142717-A1 | COMPOUNDS | LIPG, PLA2G1B, ENPP2 | ALDH1A1 3079/4885KDM4E 3871/4885SMN1; SMN2 3782/4885 |
| US-20140378487-A1 | TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES | LIPG, PCSK9, ENPP2 | ALDH1A1 3675/4885KDM4E 4272/4885SMN1; SMN2 4240/4885 |
| US-20080221139-A1 | Novel Compounds | MMP9, MMP2, MMP1 | ALDH1A1 282/4885KDM4E 1320/4885SMN1; SMN2 1975/4885 |
| US-20120232101-A1 | Novel Compounds | MMP9, MMP2, MMP1 | ALDH1A1 282/4885KDM4E 1320/4885SMN1; SMN2 1975/4885 |
| US-20150099756-A1 | PYRIMIDINONE COMPOUNDS FOR USE IN THE TREATMENT OF DISEASES OR CONDITIONS MEDIATED BY LP-PLA2 | PLA2G1B, PLA2G4A, PLA2G4B | ALDH1A1 2042/4885KDM4E 3085/4885SMN1; SMN2 2782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.